Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 2,870 matching trials from the live ClinicalTrials.gov search.
Conditions
AML, ALL, Lymphoid Malignancies, Myelodysplastic Syndromes, CML, Primary Myelofibrosis
Interventions
Infusion of CD34 selected hematopoietic stem cells
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
4 Weeks to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Unspecified Complication of Bone Marrow Transplant
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
10 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Olanzapine 5 MG, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Ewing's Sarcoma, Rhabdomyosarcoma
Interventions
therapeutic autologous dendritic cells, indinavir sulfate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 35 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
Interventions
Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation
Biological · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 71 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Seattle, Washington
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Bortezomib, Dexamethasone, Daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
36
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 33 more
Conditions
Hematologic Neoplasms, Anemia, Aplastic, Hemoglobinuria, Paroxysmal, Multiple Myeloma
Interventions
haploidentical allogeneic PBSC transp
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Active, not recruiting Phase 2 Interventional Results available

KRDI in Transplant-Eligible MM

NCT04430894
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Isatuximab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Plasma Cell Leukemia
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
11
States / cities
La Jolla, California • New Haven, Connecticut • North Haven, Connecticut + 8 more
Conditions
Leukemia, Lymphoma
Interventions
fludarabine phosphate, Cyclophosphamide, PBSC, G-CSF, Donor lymphocytes
Drug · Biological
Lead sponsor
Cancer and Leukemia Group B
Network
Eligibility
Up to 69 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
19
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 16 more
Conditions
Organ Dysfunction, Hemolysis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Etoposide, Fractionated Stereotactic Radiation Therapy, Goat Milk, Palifermin, Sirolimus, Tacrolimus
Procedure · Drug · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Duarte, California
Conditions
Graft Versus Host Disease, Graft Vs Host Disease, Hematologic Malignancy
Interventions
Belumosudil
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Leukemia
Interventions
therapeutic allogeneic lymphocytes, cyclosporine, cytarabine, fludarabine phosphate, methotrexate, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Conditions
Multiple Myeloma
Interventions
filgrastim, melphalan, autologous peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hematopoietic Cell Transplant
Interventions
MedMemos
Behavioral
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
0 Years to 12 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Wiskott-Aldrich Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Male only
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Conditions
Neuroblastoma
Interventions
3F8 monoclonal antibody and 13-cis-Retinoic Acid
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Months and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors, Hodgkin's Disease, Myelofibrosis
Interventions
Total Body Irradiation with Fludarabine in UCB Transplants
Procedure
Lead sponsor
Duke University
Other
Eligibility
14 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Lymphoma, Large-Cell, Diffuse
Interventions
Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna, Cisplatine, Cytosine Arabinoside, Dexamethasone, Autologous Stem Cell Transplantation, BCNU, Cytarabine, Melphalan
Drug · Procedure
Lead sponsor
Lymphoma Study Association
Other
Eligibility
18 Years to 65 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Diffuse Large B-cell-lymphoma
Interventions
Venetoclax, Rituximab, Ifosfamide, Carboplatin, Etoposide
Drug
Lead sponsor
Molly Gallogly
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
3
States / cities
St Louis, Missouri • Cleveland, Ohio
Conditions
Neuroblastoma
Interventions
Carboplatin, Etoposide, Melphalan, Stem Cell Infusion, ClinicMACS
Drug · Procedure · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma
Interventions
Tumor Cell Collection, Autologous Stem Cell Transplant, Melphalan, Leukapheresis, Myeloma vaccine, GM-CSF, Lenalidomide
Procedure · Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 11 more